Abstract
Aside from causing hemolytic reactions the ABO blood group system does not have an impact on outcome after allogeneic bone marrow or peripheral blood stem cell transplantation (SCT). However, only a few studies have addressed the effect of ABO incompatibility on the incidence of GVHD, time to engraftment, relapse and survival. Therefore, we performed a retrospective two-center analysis of 562 consecutive patients receiving allogeneic SCT, including 361 ABO-identical, 98 minor, 86 major and 17 bidirectional ABO-incompatible SCT. In multivariate analysis adjusted for potential confounders survival was significantly associated with ABO incompatibility (P = 0.006). Compared to ABO-identical SCT, bidirectional ABO incompatibility increased the risk significantly (RR, 2.8; 95% CI, 1.5–5.1; P = 0.0009), whereas survival of patients with minor (RR, 1.2; 95% CI, 0.9–1.7; P = 0.27), or major ABO-incompatible SCT (RR, 1.3; 95% CI, 0.9–1.8; P = 0.18) was not significantly different. RBC engraftment was delayed in major ABO-incompatible SCT (RR, 0.66; 95% CI, 0.51–0.85; P = 0.001). The incidence of acute GVHD (grade I–IV) was higher in minor ABO-incompatible SCT as compared to ABO identity (RR, 2.8; 95% CI, 1.3–5.9, P = 0.009). This difference was limited to mild GVHD; in moderate-to-severe GVHD (grade II–IV) no significant difference was found among the groups (P = 0.53). The relapse rate was not influenced by ABO incompatibility (P = 0.78). In conclusion, these results suggest that ABO incompatibility represents a risk factor not only for post-transplant hemolysis, but also for survival and the rate of mild GVHD after allogeneic SCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Klumpp TR . Immunohematologic complications of bone marrow transplantation Bone Marrow Transplant 1991 8: 159 170
Lasky LC, Warkentin PI, Kersey JH et al. Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation Transfusion 1983 23: 277 285
Petz LD . Hemolysis associated with transplantation Transfusion 1998 38: 224 228
Buckner CD, Clift RA, Sanders JE et al. ABO-incompatible marrow transplants Transplantation 1978 26: 233 238
Bensinger WI, Buckner CD, Thomas ED, Clift RA . ABO-incompatible marrow transplants Transplantation 1982 33: 427 429
Hershko C, Gale RP, Ho W, Fitchen J . ABH antigens and bone marrow transplantation Br J Haematol 1980 44: 65 73
Kalaycioglu M, Copelan E, Avalos B et al. Survival after ABO-incompatible allogeneic bone marrow transplant after a preparative regimen of busulfan and cyclophosphamide Bone Marrow Transplant 1995 15: 105 110
Benjamin RJ, McGurk S, Ralston MS et al. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation Transfusion 1999 39: 179 187
Bacigalupo A, Van Lint MT, Occhini D et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation Transplantation 1988 45: 1091 1094
Kunimasa J, Yurugi K, Ito K et al. Hemolytic reaction due to graft-versus-host (GVH) antibody production after liver transplantation from living donors: report of two cases Surg Today 1998 28: 857 861
Mielcarek M, Leisenring W, Torok-Storb B, Storb R . Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect Blood 2000 96: 1150 1156
Stussi G, Seebach L, Muntwyler J et al. GVHD and survival after allogeneic bone marrow transplantation – a single center experience Br J Haematol 2001 113: 251 253
Farges O, Kalil AN, Samuel D et al. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients Transplantation 1995 59: 1124 1133
Ishida H, Koyama I, Sawada T et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation Transplantation 2000 70: 681 685
Breimer ME, Brynger H, Le PJ et al. Blood group ABO-incompatible kidney transplantation biochemical and immunochemical studies of blood group A glycolipid antigens in human kidney and characterization of the antibody response (antigen specificity and antibody class) in O recipients receiving A2 grafts Transplant Proc 1987 19: 226 230
West LJ, Pollock-Barziv SM, Dipchand AI et al. ABO-incompatible heart transplantation in infants New Engl J Med 2001 344: 793 800
Rydberg L . ABO-incompatibility in solid organ transplantation Transfus Med 2001 11: 325 342
Auchincloss HJ, Sachs DH . Xenogeneic transplantation Annu Rev Immunol 1998 16: 433 470
Galili U . Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans Immunol Today 1993 14: 480 482
Benjamin RJ, Antin JH . ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity Transfusion 1999 39: 1273 1274
Heal JM, Blumberg N . The second century of ABO: and now for something completely different Transfusion 1999 39: 1155 1159
Lee JH, Lee KH, Kim S et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation Bone Marrow Transplant 2000 25: 179 184
Gmür JP, Burger J, Schaffner A et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation Blood 1990 75: 290 295
Matsui T, Shimoyama T, Matsumoto M et al. ABO blood group antigens on human plasma von Willebrand factor after ABO-mismatched bone marrow transplantation Blood 1999 94: 2895 2900
Szulman AE . The histological distribution of blood group substances A and B in man J Exp Med 1960 111: 785 799
Eastlund T . The histo-blood group ABO system and tissue transplantation Transfusion 1998 38: 975 988
Klumpp TR, Fairclough D, Ritz J, Soiffer R . The effect of minor ABO mismatches on the incidence of graft-versus-host disease after allogeneic bone marrow transplantation Transplantation 1994 57: 780
Acknowledgements
This work was supported by grants from the Swiss National Science Foundation (4046–058668/1) and the Julius-Müller Stiftung to JDS and a grant from the Heuberg Stiftung to GS.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stussi, G., Muntwyler, J., Passweg, J. et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 30, 87–93 (2002). https://doi.org/10.1038/sj.bmt.1703621
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703621
Keywords
This article is cited by
-
Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants
Annals of Hematology (2021)
-
Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia
Bone Marrow Transplantation (2020)
-
The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation
Bone Marrow Transplantation (2020)
-
Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT
Bone Marrow Transplantation (2015)
-
ABO, alemtuzumab and allogeneic transplantation
Bone Marrow Transplantation (2015)